ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Cementing Relentless Faith

<< Previous

Bullboard Posts

Next >>

Comment by KingAbeNYCon Aug 06, 2021 8:52am

101 Views

Post# 33662618

RE:RE:RE:RE:RE:Cementing Relentless Faith

I feel the need to reply to David as being in the Banking industry for 30 Years.
Daytraders don't care about promis, the only ones buying and why you are seeing the volume dipping by a few cents is because sectors like mine are buying in bulk and unloading at ANY time they wish regardless of the share price! Its a way to keep things moving forward as a bank.
hey if you can make a "Money" then thats all fine and dandy.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario